Anti-ALK antibodies in patients with ALK-positive malignancies not expressing NPM-ALK

Christine Damm-Welk; Faraz Siddiqi; Matthias Fischer; Barbara Hero; Vignesh Narayanan; David Ross Camidge; Michael Harris; Amos Burke; Thomas Lehrnbecher; Karen Pulford; Ilske Oschlies; Reiner Siebert; Suzanne Turner; Wilhelm Woessmann

doi:10.7150/jca.15238

Anti-ALK antibodies in patients with ALK-positive malignancies not expressing NPM-ALK

Christine Damm-Welk^*
, Faraz Siddiqi
, Matthias Fischer
, Barbara Hero
, Vignesh Narayanan
, David Ross Camidge
, Michael Harris
, Amos Burke
, Thomas Lehrnbecher
, Karen Pulford
, Ilske Oschlies
, Reiner Siebert
, Suzanne Turner
, Wilhelm Woessmann

^*Corresponding author for this work

Cancer and Genomic Sciences

Research output: Contribution to journal › Article › peer-review

Abstract

Patients with Nucleophosmin (NPM)- Anaplastic Lymphoma Kinase (ALK) fusion positive Anaplastic Large Cell Lymphoma produce autoantibodies against ALK indicative of an immune response against epitopes of the chimeric fusion protein. We asked whether ALK-expression in other malignancies induces specific antibodies. Antibodies against ALK were detected in sera of one of 50 analysed ALK-expressing neuroblastoma patients, 13 of 21 ALK positive non-small cell lung carcinoma (NSCLC) patients, 13 of 22 ALK translocation-positive, but NPM-ALK-negative lymphoma patients and one of one ALK-positive rhabdomyosarcoma patient, but not in 20 healthy adults. These data suggest that boosting a pre-existent anti-ALK immune response may be more feasible for patients with ALK-positive NSCLC, lymphomas and rhabdomyosarcomas than for tumours expressing wild-type ALK.

Original language	English
Pages (from-to)	1383-1387
Number of pages	5
Journal	Journal of Cancer
Volume	7
Issue number	11
DOIs	https://doi.org/10.7150/jca.15238
Publication status	Published - 2016

Bibliographical note

Funding Information:
The authors would like to thank the staff of the NHL-BFM laboratory for expert technical assistance.This work was supported by a grant from the Deutsche Jose Carreras Leukämie-Stiftung (DJCLS08/09) to WW, and RS. CDW and WW are additionally supported by the von behring röntgen stiftung (60-0011) and the Forschungshilfe Peiper, IO and RS by the Kinderkrebsinitiative Buchholz/Holm-Seppensen and KP by Bloodwise, the Julian Starmer-Smith Memorial Fund and the Sam Foye Fund. SDT is a Bloodwise University Senior Lecturer and is also supported by the Alex Hulme Foundation and the Sam Foye Fund. MH is supported by a PhD studentship from the Wellcome Trust.

Publisher Copyright:
© Ivyspring International Publisher.

Keywords

ALK-antibody titre
Lymphoma
Neuroblastoma
NSCLC

ASJC Scopus subject areas

Oncology

Access to Document

10.7150/jca.15238

Cite this

@article{b3b2319c2c8b4a2395e71d604bf0dda6,

title = "Anti-ALK antibodies in patients with ALK-positive malignancies not expressing NPM-ALK",

abstract = "Patients with Nucleophosmin (NPM)- Anaplastic Lymphoma Kinase (ALK) fusion positive Anaplastic Large Cell Lymphoma produce autoantibodies against ALK indicative of an immune response against epitopes of the chimeric fusion protein. We asked whether ALK-expression in other malignancies induces specific antibodies. Antibodies against ALK were detected in sera of one of 50 analysed ALK-expressing neuroblastoma patients, 13 of 21 ALK positive non-small cell lung carcinoma (NSCLC) patients, 13 of 22 ALK translocation-positive, but NPM-ALK-negative lymphoma patients and one of one ALK-positive rhabdomyosarcoma patient, but not in 20 healthy adults. These data suggest that boosting a pre-existent anti-ALK immune response may be more feasible for patients with ALK-positive NSCLC, lymphomas and rhabdomyosarcomas than for tumours expressing wild-type ALK.",

keywords = "ALK-antibody titre, Lymphoma, Neuroblastoma, NSCLC",

author = "Christine Damm-Welk and Faraz Siddiqi and Matthias Fischer and Barbara Hero and Vignesh Narayanan and Camidge, \{David Ross\} and Michael Harris and Amos Burke and Thomas Lehrnbecher and Karen Pulford and Ilske Oschlies and Reiner Siebert and Suzanne Turner and Wilhelm Woessmann",

note = "Funding Information: The authors would like to thank the staff of the NHL-BFM laboratory for expert technical assistance.This work was supported by a grant from the Deutsche Jose Carreras Leuk{\"a}mie-Stiftung (DJCLS08/09) to WW, and RS. CDW and WW are additionally supported by the von behring r{\"o}ntgen stiftung (60-0011) and the Forschungshilfe Peiper, IO and RS by the Kinderkrebsinitiative Buchholz/Holm-Seppensen and KP by Bloodwise, the Julian Starmer-Smith Memorial Fund and the Sam Foye Fund. SDT is a Bloodwise University Senior Lecturer and is also supported by the Alex Hulme Foundation and the Sam Foye Fund. MH is supported by a PhD studentship from the Wellcome Trust. Publisher Copyright: {\textcopyright} Ivyspring International Publisher.",

year = "2016",

doi = "10.7150/jca.15238",

language = "English",

volume = "7",

pages = "1383--1387",

journal = "Journal of Cancer",

issn = "1837-9664",

publisher = "Ivyspring International Publisher",

number = "11",

}

TY - JOUR

T1 - Anti-ALK antibodies in patients with ALK-positive malignancies not expressing NPM-ALK

AU - Damm-Welk, Christine

AU - Siddiqi, Faraz

AU - Fischer, Matthias

AU - Hero, Barbara

AU - Narayanan, Vignesh

AU - Camidge, David Ross

AU - Harris, Michael

AU - Burke, Amos

AU - Lehrnbecher, Thomas

AU - Pulford, Karen

AU - Oschlies, Ilske

AU - Siebert, Reiner

AU - Turner, Suzanne

AU - Woessmann, Wilhelm

N1 - Funding Information: The authors would like to thank the staff of the NHL-BFM laboratory for expert technical assistance.This work was supported by a grant from the Deutsche Jose Carreras Leukämie-Stiftung (DJCLS08/09) to WW, and RS. CDW and WW are additionally supported by the von behring röntgen stiftung (60-0011) and the Forschungshilfe Peiper, IO and RS by the Kinderkrebsinitiative Buchholz/Holm-Seppensen and KP by Bloodwise, the Julian Starmer-Smith Memorial Fund and the Sam Foye Fund. SDT is a Bloodwise University Senior Lecturer and is also supported by the Alex Hulme Foundation and the Sam Foye Fund. MH is supported by a PhD studentship from the Wellcome Trust. Publisher Copyright: © Ivyspring International Publisher.

PY - 2016

Y1 - 2016

N2 - Patients with Nucleophosmin (NPM)- Anaplastic Lymphoma Kinase (ALK) fusion positive Anaplastic Large Cell Lymphoma produce autoantibodies against ALK indicative of an immune response against epitopes of the chimeric fusion protein. We asked whether ALK-expression in other malignancies induces specific antibodies. Antibodies against ALK were detected in sera of one of 50 analysed ALK-expressing neuroblastoma patients, 13 of 21 ALK positive non-small cell lung carcinoma (NSCLC) patients, 13 of 22 ALK translocation-positive, but NPM-ALK-negative lymphoma patients and one of one ALK-positive rhabdomyosarcoma patient, but not in 20 healthy adults. These data suggest that boosting a pre-existent anti-ALK immune response may be more feasible for patients with ALK-positive NSCLC, lymphomas and rhabdomyosarcomas than for tumours expressing wild-type ALK.

AB - Patients with Nucleophosmin (NPM)- Anaplastic Lymphoma Kinase (ALK) fusion positive Anaplastic Large Cell Lymphoma produce autoantibodies against ALK indicative of an immune response against epitopes of the chimeric fusion protein. We asked whether ALK-expression in other malignancies induces specific antibodies. Antibodies against ALK were detected in sera of one of 50 analysed ALK-expressing neuroblastoma patients, 13 of 21 ALK positive non-small cell lung carcinoma (NSCLC) patients, 13 of 22 ALK translocation-positive, but NPM-ALK-negative lymphoma patients and one of one ALK-positive rhabdomyosarcoma patient, but not in 20 healthy adults. These data suggest that boosting a pre-existent anti-ALK immune response may be more feasible for patients with ALK-positive NSCLC, lymphomas and rhabdomyosarcomas than for tumours expressing wild-type ALK.

KW - ALK-antibody titre

KW - Lymphoma

KW - Neuroblastoma

KW - NSCLC

UR - https://www.scopus.com/pages/publications/84994228701

U2 - 10.7150/jca.15238

DO - 10.7150/jca.15238

M3 - Article

AN - SCOPUS:84994228701

SN - 1837-9664

VL - 7

SP - 1383

EP - 1387

JO - Journal of Cancer

JF - Journal of Cancer

IS - 11

ER -

Anti-ALK antibodies in patients with ALK-positive malignancies not expressing NPM-ALK

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

Access to Document

Fingerprint

Cite this